New clinical guideline - Proton Pump Inhibitor Guideline for Neonates and Paediatrics
NHSGGC guidance on the use proton pump inhibitors (PPIs) in neonates and children is available here.
Key messages
-
The guideline contains information on preferred choice of PPI, as well as dosage and administration advice.
-
For the majority of paediatric patients, orodispersible tablet and capsule formulations of omeprazole and lansoprazole have been used successfully with little need for alternatives. The guidance gives advice on administration including splitting doses.
-
Licensed suspensions of oral omeprazole 10mg/5ml and 20mg/5ml are available; however there have been issues with tolerability in neonatal and paediatric patients and these are not preferred formulations for use in children in NHSGGC.
-
The NHSGGC Area Drug and Therapeutics Committee (ADTC) has endorsed, and when prescribed in primary care, the Central Prescribing Team will provide authorisation for, the use of unlicensed Aclomep omeprazole oral solution 20mg/5ml in line with restricted indications as per this guidance. Please refer to use of specials in primary care guidance.
For further information please contact prescribing@ggc.scot.nhs.uk.
Published 24/11/21. Links updated 09/03/2022.
Medicines Update blogs are correct at the time of publication.